Crescent Biopharma Inc.
CBIO | NASDAQ
$12.95
-$0.53 (-3.93%)
Nov 2, 2026, 1:19 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 | Q3 2022 Sep 30, 2022 | Q2 2022 Jun 30, 2022 | Q1 2022 Mar 31, 2022 | Q4 2021 Dec 31, 2021 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 11.88M | 11.88M | 10.84M | n/a | n/a | n/a | n/a | 10K | 10K | 10K | 10K | n/a | n/a | 75K | 75K | 92.63K | 179.19K | 104.33K | 1.16M | 1.31M | 2.22M | 2.22M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 11.88M | 11.88M | 10.84M | n/a | n/a | n/a | n/a | 10K | 10K | 10K | 10K | n/a | n/a | 75K | 75K | 92.63K | 179.19K | 104.33K | 1.16M | 1.31M | 2.22M | 2.22M |
Operating Income | -168.47M | -163.14M | -152.63M | -78.33M | -63.68M | -53.01M | -49.9M | -42.3M | -40.88M | -39.45M | -39.28M | -40.31M | -39.26M | -43.68M | -47.4M | -54.21M | -62.78M | -63.83M | -63.45M | -61.59M | -57.98M | -57.68M |
Interest Income | 5.35M | 4.13M | 2.87M | 1.96M | 861.52K | 810.81K | 1M | 1.34M | 1.76M | 2.17M | 2.38M | 2.24M | 1.87M | 1.29M | 714.52K | 340.33K | 101.36K | 20.99K | 19.77K | 21.3K | 21.44K | 42.92K |
Pretax Income | -163.12M | -160.08M | -151.94M | -79.41M | -64.63M | -52.93M | -48.52M | -39.73M | -39.11M | -37.28M | -36.9M | -38.06M | -37.39M | -42.39M | -46.69M | -53.87M | -62.68M | -63.81M | -63.43M | -61.57M | -57.96M | -57.64M |
Net Income | -162.98M | -162.08M | -153.94M | -79.41M | -64.63M | -52.93M | -48.52M | -39.74M | -39.11M | -37.28M | -36.9M | -38.07M | -37.39M | -42.4M | -46.69M | -53.87M | -62.67M | -63.81M | -63.43M | -61.57M | -57.96M | -57.64M |
Selling & General & Admin | 29.46M | 29.66M | 25.39M | 21.24M | 19.71M | 14.83M | 16.32M | 17.48M | 18M | 18.78M | 19.21M | 19.63M | 18.96M | 19.55M | 19.09M | 18.9M | 19.2M | 17.98M | 17.12M | 16.58M | 16.49M | 16.49M |
Research & Development | 152.67M | 145.36M | 138.08M | 57.09M | 38.46M | 32.66M | 28.06M | 19.31M | 22.89M | 20.68M | 20.07M | 20.67M | 20.31M | 24.21M | 28.39M | 35.4M | 43.75M | 45.95M | 47.49M | 46.32M | 43.7M | 43.41M |
Other Expenses | -1.77M | n/a | n/a | n/a | 5.51M | 5.51M | 5.51M | 5.51M | 48 | 325 | 637 | 1.05K | 927 | 567 | 443 | -760 | -387 | 78 | n/a | 324 | -98 | -523 |
Operating Expenses | 180.35M | 175.02M | 163.48M | 78.33M | 63.68M | 53.01M | 49.9M | 42.31M | 40.89M | 39.46M | 39.29M | 40.31M | 39.26M | 43.76M | 47.48M | 54.3M | 62.96M | 63.93M | 64.61M | 62.89M | 60.2M | 59.9M |
Interest Expense | n/a | 1.07M | 2.19M | 3.04M | 3.04M | 1.96M | 852K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 180.35M | 175.02M | 163.48M | 78.33M | 63.68M | 53.01M | 49.9M | 42.31M | 40.89M | 39.46M | 39.29M | 40.31M | 39.26M | 43.76M | 47.48M | 54.3M | 62.96M | 63.93M | 64.61M | 62.89M | 60.2M | 59.9M |
Income Tax Expense | 2M | 2M | 2M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 30.53M | 30.4M | 20.17M | 16.54M | 3.86M | 771.85K | 644.84K | 644.84K | 644.84K | 644.57K | 643.94K | 643.5K | 642.76K | 603.5K | 529.62K | 524.24K | 524.07K | 523.31K | 520.12K | 515.65K | 515.39K | 506.97K |
Shares Outstanding (Diluted) | 30.53M | 30.4M | 20.17M | 16.54M | 3.86M | 771.85K | 644.84K | 644.84K | 644.84K | 644.57K | 643.94K | 643.5K | 642.76K | 603.5K | 529.62K | 524.24K | 524.07K | 523.31K | 520.12K | 515.65K | 515.39K | 506.97K |
EPS (Basic) | -7.58 | -12.49 | -31.35 | -54.48 | -68.23 | -78.24 | -75.27 | -61.66 | -60.72 | -57.91 | -58.42 | -63.66 | -65.62 | -78.09 | -88.92 | -103.08 | -120.43 | -123.05 | -123.21 | -122.14 | -117.41 | -121.61 |
EPS (Diluted) | -7.58 | -12.49 | -31.35 | -54.48 | -68.23 | -78.24 | -75.27 | -61.66 | -60.72 | -57.91 | -58.42 | -63.66 | -65.62 | -78.09 | -88.92 | -103.08 | -120.43 | -123.05 | -123.21 | -122.14 | -117.41 | -121.61 |
EBITDA | -162.91M | -158.86M | -149.67M | -41.21M | -22.34M | -11.97M | -9.04M | -36.73M | -40.78M | -39.32M | -39.12M | -40.13M | -39.08M | -43.49M | -47.2M | -53.98M | -62.53M | -63.57M | -63.18M | -61.32M | -57.71M | -57.41M |
EBIT | -163.12M | -159M | -149.76M | -76.38M | -57.49M | -47.13M | -44.21M | -36.78M | -40.88M | -39.45M | -39.27M | -40.31M | -39.26M | -43.68M | -47.4M | -54.21M | -62.78M | -63.83M | -63.45M | -61.59M | -57.98M | -57.68M |
Depreciation & Amortization | 212K | 148K | 84K | 35.17M | 35.15M | 35.16M | 35.17M | 58.47K | 93.09K | 124.08K | 153.3K | 175.72K | 180.32K | 191.68K | 207.15K | 223.07K | 243.11K | 255.82K | 264.6K | 271.31K | 270.46K | 270.65K |
Add to Watchlist
Select watchlists to add or remove CBIO